PRQR - ProQR Therapeutics N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.60
+0.15 (+2.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.45
Open7.40
Bid7.55 x 1300
Ask9.05 x 2200
Day's Range7.40 - 7.70
52 Week Range2.75 - 7.75
Volume155,727
Avg. Volume92,131
Market Cap242.606M
Beta0.99
PE Ratio (TTM)N/A
EPS (TTM)-1.86
Earnings DateMay 15, 2018 - May 21, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.83
Trade prices are not sourced from all markets
  • Associated Press6 days ago

    ProQR: 2Q Earnings Snapshot

    The Leiden, Netherlands-based company said it had a loss of 27 cents per share. ProQR shares have more than doubled since the beginning of the year. The stock has risen 36 percent in the last 12 months. ...

  • GlobeNewswire6 days ago

    ProQR Announces Financial Results for the Second Quarter of 2018

    LEIDEN, The Netherlands, Aug. 08, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, ...

  • GlobeNewswire13 days ago

    ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a peer-reviewed manuscript describing the preclinical validation for the use of QR-110 in the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal Molecular Therapy - Nucleic Acids. LCA10 is a severe inherited retinal dystrophy associated with mutations in the CEP290 gene. QR-110 is an RNA-based drug candidate that has the potential to restore sight or slow down the process of vision loss in patients with LCA10 by correcting the most common mutation causing LCA10, p.Cys998X.

  • GlobeNewswirelast month

    ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July

    A presentation will be delivered by Dr. Erwin van Wijk from Radboudumc at Nijmegen, the Netherlands on QR-421a for Usher Syndrome during the USH2018 International Symposium to be held on July 19 – 21, 2018 in Mainz, Germany.

  • GlobeNewswire2 months ago

    ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

    The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene.. QR-313 is a first-in-class ...

  • GlobeNewswire2 months ago

    ProQR to Present at the JMP Life Sciences Conference

    LEIDEN, the Netherlands, June 14, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, ...

  • GlobeNewswire2 months ago

    ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced a collaboration with nonprofit organizations EB Research Partnership (EBRP) and EB Medical Research Foundation (EBMRF) to develop QR-313 for patients with dystrophic epidermolysis bullosa (DEB) caused by mutations in exon 73 of the COL7A1 gene. Under the agreement, EBRP and EBMRF will provide up to approximately $5 million in matching funding to ProQR under a venture philanthropy model, to co-fund the clinical development of QR-313.

  • ACCESSWIRE2 months ago

    Wired News – Axovant Inked $842.5 Million Licensing Deal with Oxford BioMedica to Develop OXB-102 for Parkinson’s Treatment

    LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Axovant Sciences Ltd (NASDAQ: AXON) ("Axovant"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXON as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has signed an exclusive worldwide licensing deal with Oxford BioMedica to develop and commercialize OXB-102 (now AXO-Lenti-PD), a gene therapy developed by Oxford BioMedica for Parkinson's disease utilizing the LentiVector® platform. Active-Investors.com is currently working on the research report for ProQR Therapeutics N.V. (NASDAQ: PRQR), which also belongs to the Healthcare sector as the Company Axovant Sciences.

  • GlobeNewswire2 months ago

    ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

    LEIDEN, The Netherlands, June 04, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, ...

  • GlobeNewswire3 months ago

    ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board

    ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr. Yi-Tao Yu to the company's scientific advisory board. "Dr. Yu is a pioneer of targeted RNA editing to correct protein translation defects caused by premature termination codons,” said Daniel de Boer, chief executive officer of ProQR.

  • Associated Press3 months ago

    ProQR: 1Q Earnings Snapshot

    The Leiden, Netherlands-based company said it had a loss of 41 cents per share. The company's shares closed at $4.50. A year ago, they were trading at $5.20. _____ This story was generated by Automated ...

  • How Vertex Pharmaceuticals’ Drugs Performed in 1Q18
    Market Realist4 months ago

    How Vertex Pharmaceuticals’ Drugs Performed in 1Q18

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million. It fell 3% QoQ (quarter-over-quarter).

  • Will ProQR Therapeutics (PRQR) Continue to Surge Higher?
    Zacks4 months ago

    Will ProQR Therapeutics (PRQR) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in ProQR Therapeutics N.V. (PRQR)

  • Associated Press5 months ago

    ProQR reports 4Q loss

    The Leiden, Netherlands-based company said it had a loss of 46 cents per share. For the year, the company reported that its loss widened to $49.3 million, or $1.94 per share. The company's shares closed ...

  • Where ProQR Therapeutics NV. (NASDAQ:PRQR) Stands In Terms Of Earnings Growth Against Its Industry
    Simply Wall St.6 months ago

    Where ProQR Therapeutics NV. (NASDAQ:PRQR) Stands In Terms Of Earnings Growth Against Its Industry

    After looking at ProQR Therapeutics NV.’s (NASDAQ:PRQR) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...